FDA Inspection
Mayinglong Pharmaceutical Group Co LtdMayinglong Pharmaceutical Group Co Ltd – FDA Inspection, Mar 14, 2025
Record Details
This FDA Inspection record concerns Mayinglong Pharmaceutical Group Co Ltd, with an inspection on March 14, 2025, issued by the Office of Inspections and Investigations, covering human drugs.
View Company Profile
ID · 1ad73c7c-df72-408e-a5c5-66c29048c1d6
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1264613
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.166(b)Adequate number of batches on stability
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Mayinglong Pharmaceutical Group Co Ltd
2| Date | Classification | Office | Project area |
|---|---|---|---|
| April 13, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 11, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Mayinglong Pharmaceutical Group Co Ltd
- FDA Inspection 1051249 - 2018-04-13
- FDA Inspection 955742 - 2015-12-11
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.